Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Class A Common Shares
-
Shares outstanding
-
98,656,192
-
Total 13F shares
-
5,790,080
-
Share change
-
+4,160,557
-
Total reported value
-
$10,700,000
-
Put/Call ratio
-
41%
-
Price per share
-
$1.85
-
Number of holders
-
26
-
Value change
-
+$7,691,063
-
Number of buys
-
16
-
Number of sells
-
9
Institutional Holders of Cardiol Therapeutics Inc. - Class A Common Shares (CRDL) as of Q4 2021
As of 31 Dec 2021,
Cardiol Therapeutics Inc. - Class A Common Shares (CRDL) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,790,080 shares.
The largest 10 holders included
MMCAP International Inc. SPC, Mirae Asset Global Investments Co., Ltd., Verition Fund Management LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC, TWO SIGMA ADVISERS, LP, SABBY MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, and JANE STREET GROUP, LLC.
This page lists
27
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.